Skip to content

US · BMEZ · ASSET MANAGEMENT

BlackRock Health Sciences Term Trust (BMEZ) intrinsic value and stock valuation

$15.81as of 2026-11-21 · Mkt cap 1.58B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

BlackRock Health Sciences Term Trust DCF and intrinsic value

InvestorsCraft values BMEZ with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from BMEZ’s statements →

BlackRock Health Sciences Term Trust Graham Number

Graham Number: $48.04d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Financial Services · Asset Management New York, NY 10001 blackrock.com

How the business is doing

Fiscal 2019–2024, USD

Revenue
$24.1M
20192024
Net income
$23.5M
20192024
Free cash flow
$65.5M
20192024
Total equity
$768.6M-14% 5y CAGRd
20192024

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2024, USD
20242023202220212020
Revenue$24.1M$8.19M-$-25.97M$59.7M$5.24M
Operating income$930K$8.46M$1.54M$50K$70K
Net income$23.5M$20M-$-26.47M$59.1M$79.6M
EPSd$1.77M$1.44M-$-2.1M$523.7K$705.9K
Operating cash flow$65.5M$32M-$-870K-$-21.56M-$-19.35M
Capital expenditure$0.00$0.00$0.00-$0.00$0.00
Free cash flow$65.5M$32M-$-870K-$-21.56M-$-19.35M
Total assets$774.6M$596.1M$606.1M$648.8M$554.6M
Total debt$280K$60K$680K$210K$100K
Net debt-$-70K-$0.00-$0.00-$0.00-$-110K
Total equity$768.6M$588.1M$600.2M$625.8M$545.9M
Cash and short-term investments$26.6M$0.00$0.00$0.00$210K
Income statement
20242023202220212020
Revenue$24.1M$8.19M-$-25.97M$59.7M$5.24M
Cost of revenue$0.00-$-8.46M$0.00$0.00$0.00
Gross profit$24.1M$28.9M-$-25.97M$6.4M$5.24M
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$360K$300K$360K$6.35M$5.17M
Other expenses$260K$90K-$-26.33M$0.00$0.00
Operating expenses$620K$390K-$-25.97M$6.35M$5.17M
Cost and expenses$620K$6.19M-$-25.97M$540K$80.1M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$0.00$0.00$230K$0.00$210K
Ebitda$930K$20M-$-26.47M$50K$0.00
Operating income$930K$8.46M$1.54M$50K$70K
Total other income/expenses, net$22.5M$11.6M-$-28.01M$0.00$79.6M
Income before tax$23.5M$20M-$-26.47M$59.1M$79.6M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income$23.5M$20M-$-26.47M$59.1M$79.6M
Weighted average shares outstanding$13.3M$13.9M$12.6M$112.9M$112.7M
Weighted average diluted shares outstanding$13.3M$13.9M$12.6M$112.9M$112.7M
Balance sheet
20242023202220212020
Cash and short-term investments$26.6M$0.00$0.00$0.00$210K
Net receivables$1.2M$1.58M$2.37M$3.18M$380K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$26.6M-$-40K$0.00$0.00$410K
Property, plant and equipment, net$0.00$0.00$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$773.3M$594.4M$603.7M$645.5M$553.1M
Total non-current assets$773.3M$594.4M$606.1M$648.8M-$-2.51B
Total assets$774.6M$596.1M$606.1M$648.8M$554.6M
Accounts payable$0.00$0.00$230K$12.5M$110K
Short-term debt$280K$60K$680K$210K$100K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$0.00$0.00$0.00$12.5M$8.62M
Long-term debt$150K$60K$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$6.03M$7.97M$5.7M$10.6M$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$6.03M$7.97M$5.93M$23M$8.62M
Common stock$942.1M$417.6M$424.3M$390.5M$339.1M
Retained earnings-$-173.53M$170.5M$175.9M$235.3M$206.8M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$768.6M$588.1M$600.2M$625.8M$545.9M
Total investments$799.8M$594.4M$603.7M$645.5M$3.07B
Total debt$280K$60K$680K$210K$100K
Net debt-$-70K-$0.00-$0.00-$0.00-$-110K
Cash flow statement
20242023202220212020
Net income$23.5M$20M-$-26.47M$59.1M$79.6M
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Stock-based compensation$0.00$0.00$0.00$0.00$0.00
Change in working capital$510K-$-770K$330K$250K-$-390K
Accounts receivable$220K-$-20K-$-150K$10K$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00-$-270K
Net cash provided by operating activities$65.5M$32M-$-870K-$-21.56M-$-19.35M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$0.00-$-40K-$-970K
Common stock issued$0.00$3.02M$33.6M$50.3M$45.1M
Common stock repurchased-$-29.53M$0.00$0.00$0.00$0.00
Dividends paid-$-35.92M-$-35.1M-$-32.73M-$-29M-$-25.65M
Net cash used for financing activities-$-65.52M-$-32.02M$880K$21.3M$19.4M
Net change in cash$10K-$0.00$0.00-$-210K$90K
Cash at end of period$10K$0.00$0.00$0.00$210K
Operating cash flow$65.5M$32M-$-870K-$-21.56M-$-19.35M
Capital expenditure$0.00$0.00$0.00-$0.00$0.00
Free cash flow$65.5M$32M-$-870K-$-21.56M-$-19.35M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About BlackRock Health Sciences Term Trust

        BlackRock Health Sciences Term Trust is a closed-end management investment company, which investment objectives are to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The company was founded on August 14, 2019 and is headquartered in Wilmington, DE.

        CEO
        John Perlowski
        Employees
        0
        Beta
        0.84

        Explore

        Frequently asked questions

        What is the intrinsic value of BlackRock Health Sciences Term Trust (BMEZ)?

        BlackRock Health Sciences Term Trust (BMEZ) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is BMEZ undervalued?

        BMEZ trades at a price of $15.81 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.